{"id":"W4367395065","doi":"10.1038/s41416-023-02279-x","title":"A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer","year":2023,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Cancer Research UK; Incyte; NuCana; Astex Pharmaceuticals; Carrick Therapeutics; Sierra Oncology; National Institute for Health and Care Research; Verastem Oncology","keywords":"Medicine; Cancer; Oncology; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001122613,0.001377912,0.001702076,0.0004087306,0.0004071002,0.0007291527,0.0005283741,0.0008640177,0.004314356],"category_scores_gemma":[0.0004869488,0.0003992066,0.0007933665,0.0004259473,0.0007484732,0.0005810842,0.0002480973,0.002195116,0.0007629204],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008369875,"about_ca_system_score_gemma":0.001789608,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001141116,"about_ca_topic_score_gemma":0.003380426,"domain_scores_codex":[0.9997107,0.0001361506,0.00001084796,0.00004807279,0.00002767119,0.00006654956],"domain_scores_gemma":[0.9996833,0.00005481192,0.00004870008,0.00002043316,0.00002801161,0.0001647748],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6000085,0.0693773,0.006417683,0.001469273,0.001206613,0.0006925309,0.0003636967,0.004597836,0.1336193,0.0005826803,0.01095043,0.1707142],"study_design_scores_gemma":[0.4993989,0.4790986,0.008059617,0.00004096121,0.0003966325,0.0003452885,0.00006161309,0.002243858,0.006614206,0.0002475377,0.003458931,0.00003375088],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912889,0.001718572,0.0005488612,0.0004603974,0.0001279795,0.002982731,0.00104424,0.0001459351,0.001682394],"genre_scores_gemma":[0.9881713,0.001719141,0.001827354,0.0006611772,0.0001847475,0.002131973,0.002339788,0.00003661185,0.00292787],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004314356,"threshold_uncertainty_score":0.01443297,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009254080624268702,"score_gpt":0.2939590683124058,"score_spread":0.2847049876881371,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}